Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
65.04%
Operating Margin
53.07%
Net Margin
1.22%
Efficiency Metrics
Revenue per Expense Ratio
2.13
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
53.03%
Income Tax Rate
89,400,000.0%
EPS
0.1700000000
Balance Sheet Analysis
Current Ratio
5.19
Cash Ratio
1.16
Working Capital
$444.00M
Debt to Equity
5.80
Debt to Assets
81.85%
Equity Ratio
14.10%
Cash Flow Analysis
Operating Cash Flow Ratio
35.27%
Free Cash Flow Ratio
34.78%
CapEx to Revenue
0.50%
Dividends Paid
$118.09M
Stock Buybacks
$4.29M
Total Shareholder Returns
$122.39M
Cash Position Change
175.23%
Key Takeaways (2023 FY)
Revenue declined by 4.9244155087556%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 374.81%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-4.92%
Net Income
106.58%
EPS
105.14%
Operating Income
296.45%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-4.68%
Operating Cash Flow
-11.87%
Free Cash Flow
-10.04%
Balance Sheet Health
Assets
-10.17%
Debt
-6.71%
Book Value per Share
-13.56%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
374.81%
Shares Outstanding
4.18%
Long Term Trends
3Y Revenue/Share
465.03%
5Y Revenue/Share
243.55%
3Y Dividend/Share
0.00%
5Y Dividend/Share
256.16%